世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い
 Tuberculosis Diagnostics Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2032 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America and Middle East and Africa)
The global tuberculosis diagnostics market is witnessing robust growth, spurred by technological advancements, increasing awareness, and growing demand for early and accurate disease detection. As ... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe global tuberculosis diagnostics market is witnessing robust growth, spurred by technological advancements, increasing awareness, and growing demand for early and accurate disease detection. As tuberculosis (TB) remains a significant public health challenge, the market is expected to expand from a value of US$2.44 billion in 2025 to US$3.76 billion by 2032, registering a compound annual growth rate (CAGR) of 6.35% during the forecast period. The market is being shaped by efforts to modernize diagnostic approaches, reduce disease burden, and improve healthcare access across high-risk regions.Market Insights Tuberculosis, caused by Mycobacterium tuberculosis, primarily affects the lungs but can impact other organs. While latent TB infections often show no symptoms, active TB can be fatal without timely diagnosis and treatment. The need for rapid, precise, and accessible diagnostic solutions has grown steadily with rising TB prevalence. Healthcare providers and diagnostic companies are increasingly focusing on the commercialization of advanced testing technologies to address the challenges in detecting and managing TB. Innovations in molecular diagnostics, such as nucleic acid amplification tests, are transforming disease detection by offering higher sensitivity and faster results. Key Market Drivers One of the main factors contributing to the market’s growth is the rapid development of diagnostic technologies. Molecular tests like PCR and GeneXpert have significantly improved the accuracy and speed of TB detection. These tools can identify TB bacteria and drug resistance patterns more reliably than traditional methods, supporting better clinical outcomes. Furthermore, the integration of artificial intelligence (AI) and automation in diagnostics is streamlining testing processes, improving data accuracy, and enhancing patient management. Technological innovation continues to push the boundaries of what is possible in tuberculosis diagnosis. Governments and global health agencies are also playing a key role by allocating funding and launching TB awareness and control programs. Initiatives by organizations such as the WHO and the Global Fund have accelerated diagnostic access in high-burden regions, especially in resource-constrained areas. Opportunities for Market Expansion One of the most promising areas of growth lies in point-of-care (POC) diagnostics. These solutions enable healthcare providers to conduct TB tests at or near the site of care, including clinics, remote areas, and community health centers. POC testing is critical for early detection and timely treatment, particularly in underserved populations where access to centralized labs is limited. Innovative POC tests, such as rapid molecular assays and immunoassays, offer quick results and can operate with minimal infrastructure. As global healthcare shifts toward decentralized testing and equitable diagnostics, the demand for cost-effective and user-friendly POC solutions is expected to rise significantly. This trend also opens doors for smaller diagnostic firms and startups developing affordable and mobile TB testing solutions, especially in markets with unmet needs and high disease prevalence. Regional Overview Asia Pacific continues to lead the global tuberculosis diagnostics market, driven by high TB incidence, evolving healthcare policies, and substantial investments in diagnostic infrastructure. The region benefits from a growing scientific community, increasing awareness, and government-supported programs aimed at controlling the disease. Emerging economies in South Asia are showing strong potential due to healthcare reforms, expanded research capabilities, and improved access to modern medical technologies. These factors are making the region an attractive destination for both established and emerging diagnostic players. Africa and Latin America are also showing positive signs, with increased support from international donors and growing participation in national TB programs. Meanwhile, North America and Europe remain hubs for research, innovation, and product development, supporting global market advancement. Leading Companies in the Market The competitive Analysis of the tuberculosis diagnostics market features a blend of global leaders and emerging innovators. Major players with extensive portfolios in molecular and rapid diagnostics include: • Abbott • QIAGEN • Thermo Fisher Scientific Inc. • Becton Dickinson (BD) • F. Hoffmann-La Roche AG • Hologic, Inc. • Cepheid • DiaSorin S.p.A. • Hain Lifescience GmbH • Oxford Immunotec These companies are investing in research and development, strategic partnerships, and market expansion to enhance diagnostic reach and performance. Emerging companies are also gaining traction by introducing digital diagnostic solutions and low-cost alternatives tailored for low-resource settings. Industry Updates Recent developments highlight the dynamic nature of the market. In March 2024, Canadian health-tech company Noze received a $1.8 million grant to conduct a clinical trial focused on TB detection. In November 2023, Revvity introduced its FDA-approved T-SPOT TB test in India, a key step toward addressing the country’s high TB burden with advanced IGRA-based screening. These advancements underscore the growing commitment among public and private sectors to develop faster, more accessible, and scalable diagnostic solutions. Challenges to Market Growth Despite promising growth, several challenges persist. Inadequate healthcare infrastructure in low- and middle-income countries remains a significant barrier. Many facilities lack essential equipment, trained personnel, and reliable supply chains to support modern TB diagnostics. The high costs associated with advanced technologies like molecular assays also limit adoption in financially constrained markets. The upfront investments required for purchasing and maintaining these tools are often beyond the reach of small clinics and public healthcare systems. Addressing these issues through partnerships, subsidies, and technology transfer initiatives is critical to unlocking the full potential of the tuberculosis diagnostics market. Market Segmentation By Test Type: • Nucleic Acid Testing • SMEAR Microscopy • Radiography Tests By End User: • Hospitals & Clinics • Diagnostics Centres By Region: • North America • Latin America • Europe • Asia Pacific • The Middle East & Africa Table of Contents1. Executive Summary1.1. Global Tuberculosis Diagnostics Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value, 2025 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. Porter’s Five Forces Analysis 2.5. COVID-19 Impact Analysis 2.5.1. Supply 2.5.2. Demand 2.6. Impact of Ukraine-Russia Conflict 2.7. Economic Overview 2.7.1. World Economic Projections 2.8. PESTLE Analysis 3. Global Tuberculosis Diagnostics Market Outlook, 2019-2032 3.1. Global Tuberculosis Diagnostics Market Outlook, by Test Type, Value (US$ Bn), 2019-2032 3.1.1. Key Highlights 3.1.1.1. Sputum Smear Microscopy 3.1.1.2. Nucleic Acid Testing 3.1.1.3. Phage Assay 3.1.1.4. Cytokine Detection Assay 3.1.1.5. Radiography Tests 3.1.1.6. Others 3.2. Global Tuberculosis Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032 3.2.1. Key Highlights 3.2.1.1. Diagnostic Centers 3.2.1.2. Hospitals 3.2.1.3. Others 3.3. Global Tuberculosis Diagnostics Market Outlook, by Region, Value (US$ Bn), 2019-2032 3.3.1. Key Highlights 3.3.1.1. North America 3.3.1.2. Europe 3.3.1.3. Asia Pacific 3.3.1.4. Latin America 3.3.1.5. Middle East & Africa 4. North America Tuberculosis Diagnostics Market Outlook, 2019-2032 4.1. North America Tuberculosis Diagnostics Market Outlook, by Test Type, Value (US$ Bn), 2019-2032 4.1.1. Key Highlights 4.1.1.1. Sputum Smear Microscopy 4.1.1.2. Nucleic Acid Testing 4.1.1.3. Phage Assay 4.1.1.4. Cytokine Detection Assay 4.1.1.5. Radiography Tests 4.1.1.6. Others 4.2. North America Tuberculosis Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032 4.2.1. Key Highlights 4.2.1.1. Diagnostic Centers 4.2.1.2. Hospitals 4.2.1.3. Others 4.3. North America Tuberculosis Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019-2032 4.3.1. Key Highlights 4.3.1.1. U.S. Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 4.3.1.2. U.S. Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 4.3.1.3. Canada Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 4.3.1.4. Canada Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 4.3.2. BPS Analysis/Market Attractiveness Analysis 5. Europe Tuberculosis Diagnostics Market Outlook, 2019-2032 5.1. Europe Tuberculosis Diagnostics Market Outlook, by Test Type, Value (US$ Bn), 2019-2032 5.1.1. Key Highlights 5.1.1.1. Sputum Smear Microscopy 5.1.1.2. Nucleic Acid Testing 5.1.1.3. Phage Assay 5.1.1.4. Cytokine Detection Assay 5.1.1.5. Radiography Tests 5.1.1.6. Others 5.2. Europe Tuberculosis Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032 5.2.1. Key Highlights 5.2.1.1. Diagnostic Centers 5.2.1.2. Hospitals 5.2.1.3. Others 5.3. Europe Tuberculosis Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019-2032 5.3.1. Key Highlights 5.3.1.1. Germany Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 5.3.1.2. Germany Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 5.3.1.3. U.K. Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 5.3.1.4. U.K. Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 5.3.1.5. France Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 5.3.1.6. France Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 5.3.1.7. Italy Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 5.3.1.8. Italy Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 5.3.1.9. Turkey Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 5.3.1.10. Turkey Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 5.3.1.11. Russia Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 5.3.1.12. Russia Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 5.3.1.13. Rest of Europe Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 5.3.1.14. Rest of Europe Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 5.3.2. BPS Analysis/Market Attractiveness Analysis 6. Asia Pacific Tuberculosis Diagnostics Market Outlook, 2019-2032 6.1. Asia Pacific Tuberculosis Diagnostics Market Outlook, by Test Type, Value (US$ Bn), 2019-2032 6.1.1. Key Highlights 6.1.1.1. Sputum Smear Microscopy 6.1.1.2. Nucleic Acid Testing 6.1.1.3. Phage Assay 6.1.1.4. Cytokine Detection Assay 6.1.1.5. Radiography Tests 6.1.1.6. Others 6.2. Asia Pacific Tuberculosis Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032 6.2.1. Key Highlights 6.2.1.1. Diagnostic Centers 6.2.1.2. Hospitals 6.2.1.3. Others 6.3. Asia Pacific Tuberculosis Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019-2032 6.3.1. Key Highlights 6.3.1.1. China Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 6.3.1.2. China Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 6.3.1.3. Japan Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 6.3.1.4. Japan Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 6.3.1.5. South Korea Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 6.3.1.6. South Korea Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 6.3.1.7. India Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 6.3.1.8. India Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 6.3.1.9. Southeast Asia Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 6.3.1.10. Southeast Asia Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 6.3.1.11. Rest of Asia Pacific Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 6.3.1.12. Rest of Asia Pacific Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 6.3.2. BPS Analysis/Market Attractiveness Analysis 7. Latin America Tuberculosis Diagnostics Market Outlook, 2019-2032 7.1. Latin America Tuberculosis Diagnostics Market Outlook, by Test Type, Value (US$ Bn), 2019-2032 7.1.1. Key Highlights 7.1.1.1. Sputum Smear Microscopy 7.1.1.2. Nucleic Acid Testing 7.1.1.3. Phage Assay 7.1.1.4. Cytokine Detection Assay 7.1.1.5. Radiography Tests 7.1.1.6. Others 7.2. Latin America Tuberculosis Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032 7.2.1. Key Highlights 7.2.1.1. Diagnostic Centers 7.2.1.2. Hospitals 7.2.1.3. Others 7.3. Latin America Tuberculosis Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019-2032 7.3.1. Key Highlights 7.3.1.1. Brazil Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 7.3.1.2. Brazil Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 7.3.1.3. Mexico Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 7.3.1.4. Mexico Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 7.3.1.5. Argentina Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 7.3.1.6. Argentina Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 7.3.1.7. Rest of Latin America Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 7.3.1.8. Rest of Latin America Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 7.3.2. BPS Analysis/Market Attractiveness Analysis 8. Middle East & Africa Tuberculosis Diagnostics Market Outlook, 2019-2032 8.1. Middle East & Africa Tuberculosis Diagnostics Market Outlook, by Test Type, Value (US$ Bn), 2019-2032 8.1.1. Key Highlights 8.1.1.1. Sputum Smear Microscopy 8.1.1.2. Nucleic Acid Testing 8.1.1.3. Phage Assay 8.1.1.4. Cytokine Detection Assay 8.1.1.5. Radiography Tests 8.1.1.6. Others 8.2. Middle East & Africa Tuberculosis Diagnostics Market Outlook, by End User, Value (US$ Bn), 2019-2032 8.2.1. Key Highlights 8.2.1.1. Diagnostic Centers 8.2.1.2. Hospitals 8.2.1.3. Others 8.3. Middle East & Africa Tuberculosis Diagnostics Market Outlook, by Country, Value (US$ Bn), 2019-2032 8.3.1. Key Highlights 8.3.1.1. GCC Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 8.3.1.2. GCC Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 8.3.1.3. South Africa Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 8.3.1.4. South Africa Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 8.3.1.5. Egypt Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 8.3.1.6. Egypt Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 8.3.1.7. Nigeria Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 8.3.1.8. Nigeria Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 8.3.1.9. Rest of Middle East & Africa Tuberculosis Diagnostics Market by Test Type, Value (US$ Bn), 2019-2032 8.3.1.10. Rest of Middle East & Africa Tuberculosis Diagnostics Market by End User, Value (US$ Bn), 2019-2032 8.3.2. BPS Analysis/Market Attractiveness Analysis 9. Competitive Landscape 9.1. Company Market Share Analysis, 2025 9.2. Competitive Dashboard 9.3. Company Profiles 9.3.1. BD 9.3.1.1. Company Overview 9.3.1.2. Product Portfolio 9.3.1.3. Financial Overview 9.3.1.4. Business Strategies and Development 9.3.2. QIAGEN 9.3.2.1. Company Overview 9.3.2.2. Product Portfolio 9.3.2.3. Financial Overview 9.3.2.4. Business Strategies and Development 9.3.3. Abbott 9.3.3.1. Company Overview 9.3.3.2. Product Portfolio 9.3.3.3. Financial Overview 9.3.3.4. Business Strategies and Development 9.3.4. Thermo Fisher Scientific Inc. 9.3.4.1. Company Overview 9.3.4.2. Product Portfolio 9.3.4.3. Financial Overview 9.3.4.4. Business Strategies and Development 9.3.5. Hologic Inc. 9.3.5.1. Company Overview 9.3.5.2. Product Portfolio 9.3.5.3. Financial Overview 9.3.5.4. Business Strategies and Development 9.3.6. DiaSorin S.p.A. 9.3.6.1. Company Overview 9.3.6.2. Product Portfolio 9.3.6.3. Financial Overview 9.3.6.4. Business Strategies and Development 9.3.7. Oxford Immunotec 9.3.7.1. Company Overview 9.3.7.2. Product Portfolio 9.3.7.3. Financial Overview 9.3.7.4. Business Strategies and Development 9.3.8. Hain Lifescience GmbH 9.3.8.1. Company Overview 9.3.8.2. Product Portfolio 9.3.8.3. Financial Overview 9.3.8.4. Business Strategies and Development 9.3.9. F. Hoffman-La Roche AG 9.3.9.1. Company Overview 9.3.9.2. Product Portfolio 9.3.9.3. Financial Overview 9.3.9.4. Business Strategies and Development 9.3.10. Danaher 9.3.10.1. Company Overview 9.3.10.2. Product Portfolio 9.3.10.3. Financial Overview 9.3.10.4. Business Strategies and Development 9.3.11. bioMérieux SA 9.3.11.1. Company Overview 9.3.11.2. Product Portfolio 9.3.11.3. Financial Overview 9.3.11.4. Business Strategies and Development 10. Appendix 10.1. Research Methodology 10.2. Report Assumptions 10.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医療IT）の最新刊レポート
Fairfield Market Research社のヘルスケアIT分野での最新刊レポート
本レポートと同じKEY WORD（tuberculosis）の最新刊レポート
よくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
